APR 08, 2017 10:38 AM PDT

FDA Approves 10 At-Home Genetic Tests

WRITTEN BY: Xuan Pham

Any person curious about their personal genetic predisposition to 10 relatively well-known diseases can now do it in the comfort of their own home, sans physician referrals. This is thanks to the FDA’s newest ruling, which will allow 23andme to sell these genetic risk tests straight to consumers.

“Consumers can now have direct access to certain genetic risk information,” said Jeffrey Shuren, the director of the FDA’s Center for Devices and Radiological Health. “But it is important that people understand that genetic risk is just one piece of the bigger puzzle, it does not mean they will or won’t ultimately develop a disease.”

This is an important distinction. The tests aren’t meant to dole out any diagnosis. Rather, these are intended to assess a person’s genetic risks of developing such disease, given their genetic profile. And to Dr. Shuren’s last point, high risks don’t necessarily mean the disease will definitely manifest, as lifestyle and other environmental factors also influence the outcome.

According to the FDA’s announcement, the 10 tests approved for direct-to-consumer (DTC) use include:

  • Parkinson’s disease: a nervous system disorder impacting movement;

  • Late-onset Alzheimer’s disease: a progressive brain disorder that destroys memory and thinking skills;

  • Celiac disease: a disorder resulting in the inability to digest gluten;

  • Alpha-1 antitrypsin deficiency: a disorder that raises the risk of lung and liver disease;

  • Early-onset primary dystonia: a movement disorder involving involuntary muscle contractions and other uncontrolled movements;

  • Factor XI deficiency: a blood clotting disorder;

  • Gaucher disease type 1: an organ and tissue disorder;

  • Glucose-6-Phosphate Dehydrogenase deficiency (G6PD): a red blood cell condition;

  • Hereditary hemochromatosis: an iron overload disorder; and

  • Hereditary thrombophilia: a blood clot disorder.

These 10 genetic health risk (GHR) test were approved based on extensive data “from peer-reviewed, scientific literature that demonstrated a link between specific genetic variants and each of the 10 health conditions,” per the FDA. The company 23andme also had to demonstrate that sufficient genetic information concerning these 10 GHR tests could be gleaned from just a saliva sample.

"This is an important moment for people who want to know their genetic health risks and be more proactive about their health," said Anne Wojcicki, the CEO and co-founder of 23andMe, in a press release.

But consumers should beware. Getting the GHR test results is only one part of the puzzle; accurately deciphering these results is arguable much trickier. According to the FDA release, results of these DTC tests should “be communicated in a way that consumers can understand and use.” Even so, because the origins of these diseases are complex, involving the interplay between genes and environmental factors, it probably would be wise to seek help from trained genetic counselors in interpreting these results.

Of note, curious consumers would also do well to consider that some diseases on this list, such as Parkinson’s and Alzheimer’s disease, don’t yet have cures. While this information may benefit people who have a family history, it may also bring undue stress for others and their families. So while knowledge is power, taking genetic tests should not be taken lightly.

Additional Source: NPR, CNN

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 31, 2021
Clinical & Molecular DX
Researchers Create the First Saliva Wiki
MAY 31, 2021
Researchers Create the First Saliva Wiki
A new digital platform, developed by researchers at the University at Buffalo, is answering the question: what’s o ...
AUG 31, 2021
Clinical & Molecular DX
Five Questions to Help You Select the Best Cellular Stain
AUG 31, 2021
Five Questions to Help You Select the Best Cellular Stain
Cellular stains are organic fluorescent dyes or fluorescent conjugates designed to localize to a specific organelle or c ...
AUG 31, 2021
Clinical & Molecular DX
How Quickly Will Alzheimer's Progress? Inflammatory Proteins Have the Answers.
AUG 31, 2021
How Quickly Will Alzheimer's Progress? Inflammatory Proteins Have the Answers.
Alzheimer's is a neurodegenerative disease that affects over 26 million worldwide and is associated with memory prob ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 14, 2021
Clinical & Molecular DX
HIV Self-Test App Proves Promising
SEP 14, 2021
HIV Self-Test App Proves Promising
A new app allows users to self-test for HIV, which has proven to help positive patients get access to medical care and c ...
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
Loading Comments...